Biotest AG / Key word(s): Offer
Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
07-Jan-2022 / 13:51 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
Dreieich, 7 January 2022. In accordance with Sections 23 para. 1 sentence 1 no. 2, no. 4 of the German Securities Acquisition and Takeover Act (WpÜG), Grifiols, S.A. has today published on its website at https://www.grifols.com/en/biotest-voluntary-takeover-offer that it holds an instrument pursuant to Section 38 para. 1 sentence 1 no. 2 of the German Securities Trading Act (WpHG) relating to 17,783,776 ordinary shares, corresponding to approximately 89.88% of the voting rights in Biotest AG. Furthermore, Grifols, S.A. states in the announcement that the total number of shares of Biotest AG for which the takeover offer of Grifols, S.A. dated 26 October 2021 was accepted until the expiry of the acceptance period (4 January 2022, 24:00 hours Frankfurt am Main local time), plus the voting rights resulting from the aforementioned instrument, corresponds to approximately 95.5498 % of the voting rights and approximately 47,7749 % of the share capital of Biotest AG. The completion of the takeover offer still depends on the occurrence of several offer conditions.
According to today’s publication, Grilfols, S.A. will be, upon settlement of the takeover offer, entitled to submit an application pursuant to Section 39a para. 1 sentence 1 WpÜG for the transfer of the remaining ordinary shares of Biotest AG in exchange for a reasonable compensation by means of a court order (so called “squeeze-out”). This does not apply to preference shares of Biotest AG. In section 9.4 of the offer document published on 26 October 2021, Grifols, S.A. stated its intention, in the event that the relevant thresholds are reached, to assess the various legal options for carrying out a so-called “squeeze-out” after settlement.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
|Phone:||0 61 03 – 8 01-0|
|Fax:||0 61 03 – 8 01-150|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1266198|
|End of Announcement||DGAP News Service|